b Linezolid-dependent growth was recently reported in Staphylococcus epidermidis clinical strains carrying mutations associated with linezolid resistance. To investigate this unexpected behavior at the molecular level, we isolated active ribosomes from one of the linezolid-dependent strains and we compared them with ribosomes isolated from a wild-type strain. Both strains were grown in the absence and presence of linezolid. Detailed biochemical and structural analyses revealed essential differences in the function and structure of isolated ribosomes which were assembled in the presence of linezolid. The catalytic activity of peptidyltransferase was found to be significantly higher in the ribosomes derived from the linezolid-dependent strain. Interestingly, the same ribosomes exhibited an abnormal ribosomal subunit dissociation profile on a sucrose gradient in the absence of linezolid, but the profile was restored after treatment of the ribosomes with an excess of the antibiotic. Our study suggests that linezolid most likely modified the ribosomal assembly procedure, leading to a new functional ribosomal population active only in the presence of linezolid. Therefore, the higher growth rate of the partially linezolid-dependent strains could be attributed to the functional and structural adaptations of ribosomes to linezolid. O xazolidinone antibiotics inhibit protein synthesis by binding to the peptidyltransferase center (PTC) of the ribosome and inhibiting the growth of bacteria (1). Although it has been suggested that they are involved in the initiation of translation, many reports have been contradictory, mainly because the ratio of drug to ribosome that was used was extremely high (2). Moreover, the inhibitory effect of oxazolidinones on peptide bond formation has not been demonstrated so far, despite structural data suggesting the binding of linezolid in the peptidyltransferase center (3-5). In contrast, linezolid perturbs translational accuracy in vivo, even at concentrations lower than the MIC (6).Linezolid (LZD) was the first FDA-approved oxazolidinone used to treat serious infections due to Gram-positive bacteria. Although LZD was completely synthetic (7), resistance readily emerged and was attributed mainly to mutations in 23S rRNA and ribosomal proteins L3 and L4. Mutations in 23S rRNA implicated in linezolid resistance include not only bases near the binding site, like G2061, C2452, A2503, U2504, and G2505, but also bases that are located more distantly from the binding site, such as A2062, G2447, A2453, C2499, U2500, and G2576 (reviewed in reference 8). Additional mechanisms include acquisition of the cfr gene, which encodes a methyltransferase which modifies A2503 in 23S rRNA, and a mutation in the RlmN gene, which naturally modifies A2503 (8-14). Recently, four nosocomial Staphylococcus epidermidis isolates belonging to the same pulsed-field gel electrophoresis type were described to exhibit partial linezolid dependence, an adaptation reported for only a few antibiotics and bacterial species in the ...